MilliporeSigma Announces Completion of Schnelldorf Distribution Center Expansion

MilliporeSigma announced that its Life Science business opened a newly expanded distribution center in Schnelldorf, Germany

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced that its Life Science business has opened a newly expanded distribution center in Schnelldorf, Germany. The investment of € 180 million added 25,000 square meters to the site, almost doubling its size. It now includes a new manual down filling operation and additional space for the distribution of a wide range of products to laboratories and research facilities all around the world. The site employs 470 engineers, manufacturing, and distribution experts.

By combining manual downing filling capabilities with our distribution expertise, our customers will benefit from increased product availability and quicker delivery,” said Matthias Heinzel, Member of the Executive Board and CEO Life Science, Merck KGaA, Darmstadt, Germany. “This is critical to ensuring that medicines reach patients faster, safely, and more efficiently. This is how we do our part to impact life and health with science.”

“With this expansion, Schnelldorf is becoming one of our flagship sites, providing unique end-to-end capabilities for our Life Science customers,” said Ivan Donzelot, Head of Integrated Supply Chain Operations, Life Science business of Merck KGaA, Darmstadt, Germany. “With the full integration of manufacturing and distribution in one site, our customers can now receive even faster and better service whether they are in Europe or in other regions of the world.”

The expansion of the Schnelldorf facility is part of a multi-year investment program of the company’s Life Science business. It aims to increase the capacity and capabilities to support the growing global demand for critical drugs and to make significant contributions to public health. Since 2020, the Life Science business of Merck KGaA, Darmstadt, Germany has announced industrial capacity and capabilities expansion projects in Life Science throughout Europe, China, and the United States, of more than € 2 billion.

The Life Science business of Merck KGaA, Darmstadt, Germany is comprised of more than 50 production and testing sites and 64 distribution centers around the world and has more than 27,000 employees in 65 countries.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.